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Long-term results of carotid stenting are
competitive with surgery
Patrice Bergeron, MD,a Michel Roux, MD,b Patrick Khanoyan, MD,a Valérie Douillez, MD,a
Jacques Bras, MS,b and Joël Gay, MS,a Marseille, France
Objective: The feasibility of carotid stenting (CS) is no longer questionable, although its indications remain debatable.
Until the results of randomized trials are available, personal series and registries should help in the comparison of
long-term results of CS with those of endarterectomy. We report here the long-term results of a large series of CS in our
department with a long follow-up. This retrospective study reviews a single surgeon’s 11-year experience with CS. Our
results are compared with those of conventional surgery emanating from our own series and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET), European Carotid Surgery Trial (ECST), and Asymptomatic
Carotid Atherosclerosis Study (ACAS).
Materials andMethods:CS has been performed in our department in a single, semi-private institution for 12 years. Patients
with high lesions, and postradiotherapy and postendarterectomy stenoses were treated with CS, as were patients at high
risk for surgery. The others were operated on with conventional endarterectomy. During the study, we performed 221 CS
procedures on 193 patients (150 men and 43 women). The average follow-up was 2.7 years (1 month to 9.3 years). We
analyzed the late results in terms of prevention from stroke, the freedom from new neurologic events, and also patency
rates of the treated carotid vessels. We also identified predictors for neurologic complication and in-stent restenosis by
using univariate analysis.
Results: Life-table analyses at 10 years gave a 96% (confidence interval [CI]  3%) rate for stroke freedom, a 98% (CI 
2%) rate for fatal stroke freedom, and a primary assisted patency rate of 95% (CI  3%). Predictors for neurologic
complication were male sex (P  .008) and age >70 (P  .04), potential renal insufficiency (P  .055), location of the
lesion at the bifurcation (P  .031), femoral access site (P  .010), use of cerebral protection (P  .022), and
self-expandable stents (P .030). In-stent restenosis occurrence extended from 2 months to 4.5 years after the procedure.
The restenosis rates at 6 months, 1, 2, and 4.5 years were, respectively, 1.4%, 2.3%, 3.7%, and 5.9% (13/221).
Asymptomatic lesions (P  .039) and the use of balloon-expandable stents (P  .055) were found to be predictors of
in-stent restenosis.
Conclusion: These long-term results show that CS is competitive with conventional surgery. A more accurate selection for
CS or surgery might reduce the rate of complications after carotid stenosis repair. ( J Vasc Surg 2005;41:213-21.)The feasibility of carotid artery stenting (CS) has been
proven by a wide range of various studies,1-9 including our
own first report in 1993.1 The potential role of CS is
starting to be accepted in some particular clinical situa-
tions.10 However, its widespread use as an alternative to
carotid endarterectomy (CEA) is not yet accepted and will
depend on whether irrefutable high-level proof from ran-
domized trials can be obtained within a few years.11-12
Recent results from the Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) trial13 demonstrate the value of CS with
cerebral protection for high-risk patients at 1 year.
Meanwhile, long-term results with 5 years of
follow-up of the endovascular procedures on carotid artery
lesions have been infrequently reported. This retrospective
study analyzed these long-term results in patients treated
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stents to assess whether the results are durable or not.
MATERIAL AND METHODS
Patient cohort. During the 12-year period from Sep-
tember 1991 to September 2003, 221 CS procedures were
done in 193 patients. This is the experience of one surgeon
whose indications in favor of either surgery or stenting have
always been selective. The practice evolved through several
phases, reflecting the use of different techniques and indi-
cations. The patient selection was based at first on the
presentation of the disease (type and location) and, when
protective devices became available, on any patients at a
higher risk for surgery.
We used the following definition of patients at high risk
for surgery: severe cardiac dysfunction (New York Heart
Association [NYHA] class III and IV, or left ventricular
ejection fraction [LVEF]30%), unstable angina, require-
ment for combined carotid and coronary revascularization
by percutaneous coronary angioplasty (PTCA) or coronary
artery bypass grafting (CABG), severe pulmonary dysfunc-
tion (forced expiratory volume in 1 second [FEV1] 1l.),
hostile neck, laryngal palsy, contralateral carotid occlusion,
and intracranial tandem lesions. We had 131 patients
(67.9%) with coronary disease, cardiac failure or both, 95
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or current smoking habits, 86 (44.6%) with other patent
vascular diseases, 67 (34.7%) had hyperlipidemia, 51
(23.05%) presented with hostile necks, 36 (18.7%) had
chronic obstructive pulmonary disease, and 35 (18.1%) had
diabetes mellitus. Two or more of these risk factors were
present in 72% of the patients treated (n  139).
Demographics and etiology. The sex distribution
was 150 men (77.7%) and 43 women (22.3%). The average
age of the patients was 71.9 years (39 to 99). We did not
use CS to treat patients 65 years, except when high-risk
conditions such as recurrent stenosis were observed. Pre-
operative symptoms were mainly transient ischemic attack
(TIA) in 65 (86.66%) of 75 patients, and 118 (61.1%) of
193 were asymptomatic. Only 5 (6.67%) of the 75 symp-
tomatic patients had minor strokes, and 5 (6.67%) had
major strokes. We treated 169 de novo stenoses (76.5%),
29 recurrent stenoses (13.1%) after carotid endarterec-
tomy, 22 stenoses (9.95%) after radiation, and 1 natural
plicature (0.45%)
Patient selection. When a patient is admitted for ca-
rotid disease, the therapeutic indication is based on symp-
toms and the degree of stenosis. Symptomatic patients with
stenosis 60% and asymptomatic patients with stenosis
80% are referred for treatment. If carotid restoration is
decided, our collegial staff (gathering anesthesiologists,
cardiologists and surgeons) discuss the case according to
local risk factors and general comorbidities. Low-risk pa-
tients are operated on by carotid endarterectomy (CEA),
whereas high-risk patients are treated by CS.
The criteria we use for our case selection for CS include
local risk factors such as radiation, previous carotid surgery
or neck surgery, high lesions, anatomically limited access
for CEA (“frozen necks” from arthritis), and laryngeal palsy
make the patients more suitable for CS. General comor-
bidities may also influence the selection:
1. Cardiac risks are considered for CS:
● Severe dysfunctions such as NYHA class III and IV or
LVEF 30% favor CS.
● Myocardial infarctions with impaired LVEF or unsta-
ble angina are investigated by stress test, coronarog-
raphy, or both. Severe coronarography stenoses re-
quiring treatment are discussed for PTCA or CABG.
Staged or combined procedures can be planned ac-
cording to the symptoms and their priority.
2. Severe pulmonary dysfunction (FEV1 1 liter) favors
CS, which only requires a local anesthesia.
3. Patients with contralateral carotid occlusion or a non-
patent Willis’ circle and intracranial tandem lesions are
considered candidates for CS with filter protection not
interrupting the flow rather than CEA with shunting.
When the patient is selected for CS, the angiogram is
mainly used to evaluate the aortic arch conformity, the
quality of the vessel wall, and the carotid tortuousities.
Severe tortuousities or a diseased aortic arch (thrombus
deposit, “shaggy” aorta) are not considered as contraindi-cation for CS, which is approached in this case by cervical
access.
Patients at low risk were surgically operated on, except
in particular cases such as high lesions (above C2 or below
the clavicle), anatomically limited access for CEA, hostile
necks due to recurrent stenosis after surgery, radical neck
surgery, or radiotherapy. CS was used to treat patients at
higher risk for surgery, regardless of the location or type of
plaque. Echogenicity of the plaque was not a selection
criterion. This type of selection should not affect the long-
term results of the fate of stents.
The CS technique. The performance of CS evolved
through two phases that reflected the technical evolution
and development of endovascular devices. During the first
period, from September 1991 to December 1998, 112
stenting procedures were performed with no cerebral pro-
tection. We preferably used direct stenting with short (2
cm) balloon-expandable (BE) stents via cervical access.
During the second period, January 1999 to September
2003, we preferably performed CS with self-expanding
(SE) stents and the routine use of protective devices via
femoral access. We treated 109 carotid lesions with all
available cerebral protection technologies: occlusive bal-
loons (49%), filters (24.5%), and reverse flow system
(11.7%). In a few cases, we used several protective devices,
filters for nontolerated interruption of the blood flow or
reverse flow for high tortuousities of the internal carotid
artery (ICA), which doesn’t allow either filter placement or
retrieval (Fig 1).
The follow-up period. During the follow-up period,
antiplatelet treatment consisting of ticlopidine or clopi-
dogrel was administrated for 1 month after the procedure.
Aspirin was prescribed thereafter as a long-life treatment.
The neurologic assessment of the patients was performed
by an independent neurologist. All the patients underwent
postoperative imaging and clinical examination. The assess-
ment of stent patency and in-stent restenosis (ISR) was
achieved by a duplex scan in 100% of patients, by enhanced
computed tomography scan in 31.6%, and by angiography
in 13.2%, mainly during later hospitalizations.
Stenosis percentage was calculated with the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) method when angiography was available. On
Doppler ultrasound records, when the operator did not
mention the percentage of stenosis measured, we used the
peak systolic velocities ratios (PSVR) and peak systolic
velocities (PSV) methods to calculate it. Stenoses 50%
were assessed by PSV  120 cm/s and PSVR  1.5.
Stenoses 70% were diagnosed by PSV  220 cm/s and
PSVR  3.3.
Analysis of results. When information was received,
we focused on new neurologic events, causes of death when
available, and on ISR based on the duplex scan, as de-
scribed. Angiograms were performed when severe stenosis
was observed on duplex scan. We considered restenosis to
be a narrowing of 50% of the diameter of the carotid
artery lumen, and the stent crushing was taken into account
for BE stents with a deformity 50%. We used the defini-
roup,
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were calculated with regards to the stent occlusions, stent
deformation 50%, and ISR 50%, which were treated
with re-dilation. Primary assisted patency includes all patent
stents after re-dilation.
Statistical analysis. The statistical analysis was done at
the University of Medicine, Marseille, by a team of univer-
sity statisticians. Theoretically, multivariate analysis can
only be performed on continued quantitative variables;
therefore, we performed a univariate statistical analysis by
using the Fisher test, which remains statistically unques-
tionable even with small numbers of individuals.
Life-table analysis was performed with the Kaplan-
Meier method, using dedicated software that calculated all
the values for each 6-month interval period. Curves were
realized with Microsoft Excel. We analyzed all new neuro-
logic events reported, including ipsilateral and contralateral
TIAs, minor and major strokes, and intracerebral hemor-
rhages. The stent patency was also studied by life-table
analysis. All the curves were stopped at 10 years.
RESULTS
Early results (<30 days). The technical success rate
Fig 1. In this patient, the tortuousities of the (A) left c
allow the placement of the filter device. C, The stenting p
System protective device (ArteriA).
Table I. Results of the Fisher test for risk factors, lesion fe
carotid stenting*
Type of
predictive factor Factors
Com
Total
No. (1)
N
fa
Risk factor Renal insufficiency 40
Male sex 40
Age 70 41
Lesion factor Lesion at the bifurcation 41
Technical factors Femoral access site 41
Protected CS 41
Self-expandable stents 36
CS, carotid stenting.
*Table shows the number of cases, the global number of patients in each gwas 96.3% (213/221). We observed 10 procedural TIAs(4.5%) and 3 procedural strokes (1 ipsilateral major stroke,
1 contralateral major stroke, and 1 ipsilateral minor stroke)
(1.55%). No procedural death was reported. Considering
the 30-day period after CS, the all-stroke/death rate was 7
(3.6%) of 193, which included 2 delayed ipsilateral minor
strokes (1.04%) and 2 fatal intracerebral hemorrhages
(1.04%). We observed two stent occlusions. One appeared
within hours and the patient was immediately successfully
operated on by conventional endarterectomy. The other
occurred at 2 days and remained asymptomatic until the
patient died 9 months later of a contralateral intracerebral
hemorrhage.
The Fisher test on risk factors and comorbidities
showed (Tables I and II) that male sex (P  .008), age 70
years (P  .04) and, potentially, renal insufficiency (P 
.055) were independently associated with higher postoper-
ative neurologic complications. Amongst features of the
lesion (Tables I and II), the etiology of the lesions and their
symptomatology were not significant (P  .993 and P 
.281). However, lesions involving the bifurcation proved
to be a predictor of neurologic complications (P 0.031).
Amongst technical factors (Tables I and II), the type of
cerebral protection systems showed no incidence on neu-
on carotid artery and (B) internal carotid artery did not
ure was successfully achieved with a Parodi Anti-Emboli
es, and technical factors on neurologic complications after
tions No complication
P
th
2) % (2/1)
Total
No. (3)
No. with
factor (4) % (4/3)
7.50 198 4 2.02 .055
92.50 202 149 73.76 .008
73.17 202 114 56.44 .040
26.83 202 27 13.37 .031
53.66 201 64 31.84 .010
53.66 202 70 34.65 .022
55.56 178 63 35.39 .030
and the P value as a result of the Fisher test.omm
rocedatur
plica
o. wi
ctor (
3
37
30
11
22
22
20rologic complications (P  .478), and predilation was not
se in p
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cervical one (P .010), the use of cerebral protection (P
.022), and the use of SE rather than BE stents (P  .030)
were found to increase the risk of neurologic complications.
The follow-up period (>30 days). The average
follow-up period was 2.7 years (30 months; range, 1 to
111.6), and no patients were lost to follow-up. All new
neurologic events were assessed by an independent neurol-
ogist, either in or outside the hospital.
Death and survival during follow-up. Twenty-nine
patients (15%) died from non-neurologic causes, including
heart failure (19%) and lung cancer (15.7%). Amongst
deaths from non-neurologic causes were renal insufficiency,
ovarian cancer, and multiorgan failure, each at 6.2%. Other
causes were abdominal aortic aneurysm rupture, digestive
hemorrhage, mesenteric infarction, pancreatitis, and leuke-
mia. Two patients died of contralateral major stroke
(1.04%) and one of intracerebral hemorrhage. The percent-
age of late stroke-related deaths was 1.55%. Life-table
analysis at 10 years showed a fatal stroke freedom of 98%
(Fig 2).
Late neurologic findings.  Our results show that the
freedom from new neurologic events at 10 years is 90% (Fig
2). The overall freedom from stroke is 96%. If only the
ipsilateral neurologic events are considered, the freedom at
10 years is 92% for all types of complications and 98% for
ipsilateral strokes (Fig 3). Thus, in our series the annual
risks of a new neurologic event, new ipsilateral neurologic
event, any stroke, and ipsilateral stroke were 1%, 0.8%,
0.4%, and 0.2%, respectively.
Fate of stents
Late surgical conversions. In one case, an ipsilateral
TIA occurred 2 years after stent placement and led to
surgery. Upon exploration, the stent sealing was very nice,
but below the stent was an ulcerated plaque (Fig 4) respon-
sible for the clinical symptoms. No stent was removed
because of ISR or stent crushing.
Stent occlusions. We observed two late asymptomatic
stent occlusions (0.9%), which were due to thromboses that
Table II. Results of the Fisher test for risk factors, lesion f
after carotid stenting*
Type of
predictive factor Factors
% w
am
com
Risk factors Renal Insufficiency
Male sex 9
Age 70 7
Lesion factor Lesion at the bifurcation 2
Technical
factors
Femoral access site 5
Protected CS 5
Self-expandable stents 5
CS, Carotid stenting.
*Table shows the percentage of factors in each group of patients, the increa
with no complication, and the P value.occurred at more than 3 and 5 years.In-stent restenosis. As defined previously, the reste-
nosis rates at 6 months, 1 year, and 2 years were 1.36%,
1.8%, and 3.2%, respectively. The overall late restenosis rate
in our series was 6.8%. We observed 15 ISR in 13 patients.
One patient had a delayed bilateral ISR and another had
two ISR on two homolateral stents at the right carotid
bifurcation and the distal right internal carotid artery.
No risk factor or comorbidity was found to be an
independent predictor of ISR with the Fisher test (Tables
III and IV). Amongst lesion-related factors, we found that
asymptomatic patients had a high probability of having ISR
(P  .039), and the use of BE stents was a potential
predictor (P  .055).
Stent deformity. Redilation was necessary in only 2
(1.4%) of 144 BE stents that were crushed 50%; one was
symptomatic. Redilation was carried out under intravascu-
lar ultrasound guidance (Fig 5). Two other deformities
50% were observed but not treated.
Stent patency. We analyzed stent patency as defined
previously. Computed life-table analysis showed a primary
patency rate of 88%, and the primary assisted patency rate
was 95% (Fig 6) after redilation of restenosis and deformi-
ties 50%.
DISCUSSION
Current indications of CS remain controversial. The
first results of the SAPPHIRE trial13 and the ongoing
CREST trial11 will allow definitive conclusions to be made.
The SAPPHIRE trial gave results that are competitive with
surgery for high-risk patients. The primary end-point,
which was defined as cumulative incidence of death, stroke,
or myocardial infarction within 30 days, or death or ipsilat-
eral stroke between 31 days and 1 year, was 12.2% in the
endovascular group and 20.1% in the surgical group. From
now on, the absence of nerve damage and the low cardiac
morbidity allow CS to be considered in hostile necks and
for high-risk patients.10
The NASCET, ECST, and ACAS14-16 studies identi-
fied cohorts of patients who have a poor result or no
advantage from CEA, depending on female sex, old age,
res, and technical factors on neurologic complications
ctor
st
ions
% with factor
amongst no
complication
Increase in
complication
risk P
2.02 3.71 .055
73.76 1.25 .008
56.44 1.29 .040
13.37 2.00 .031
31.84 1.68 .010
34.56 1.55 .022
35.39 1.57 .030
ercentage between the group with complications compared with the groupeatu
ith fa
ong
plicat
7.50
2.50
3.17
6.83
3.66
3.66
5.56cardiac diseases, and contralateral occlusion. These patients
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ertheless, long-term results are the predominant issue to be
considered for CS, because this discussion could be swept
away if long-term results of CS were not satisfactory. Is
carotid stenting durable? This is the main question to be
answered, keeping in mind the primary goal to be remem-
bered is the prevention of stroke.
Freedom from stroke. The late outcome of CS has
been poorly documented. Some authors reported midterm
results of protected CS, with a neurologic stroke and death
rate 3% and the ISR rate 6%.21-25 Some of these clinical
studies report results on high-risk patients only.25 These
results are being compared to 50 years of surgical experi-
ence. Only 4 studies that included 100 patients have
reported long-term results of CS over 3 years of follow-
up.26-29. In one of these series,28 the stroke freedom at 3
years was 79%, but it was 92% and 96% in two others.27,29
Offering an average follow-up of 30 months over an
11-year period, our series demonstrated annual risks of any
stroke at 0.4% and any fatal stroke at 0% for symptomatic
patients. The annual risk of any neurologic events was 0.6%.
Our results can hardly be compared to those of surgery,
Fig 2. Life-table analysis showing a freedom from new
and 98%, respectively, at 10 years.because since 1999, CS has always been exclusively indi-cated for high-risk patients and CEA for low-risk patients.
However, we reported 10 years ago a 1.8% stroke/death
rate in high-risk patients treated by surgery.30 NASCET15
and ECST16 studies reported annual risks for symptomatic
patients of major or fatal strokes of 0.8% and 0.76%. Con-
sidering asymptomatic patients only, our series reported a
0.2% annual risk of any fatal stroke. In the ACAS trial,14 no
long-term benefit of CEA was reported in preventing
stroke and death in asymptomatic patients with contralat-
eral occlusion (absolute risk reduction was 2% at 5 years).
We found in this study that renal insufficiency, male
sex, age 70 years, and a lesion located at the bifurcation
were good predictors of early and late neurologic compli-
cations of CS. We also identified technical factors—the use
of femoral access site, cerebral protection, and self-expand-
able stents—that were independently associated with an
increased global rate of neurologic complications. Other
studies identified old age,29 preoperative symptoms,27
length of the lesion,27 and echogenicity of the plaque31 as
predictors for early new neurologic events.
Fate of stents. Criado et al32 reported an ISR rate of
3%, Henry et al of 4.7%,33 Roubin et al29 6% for BE stents
ologic events, all strokes, and fatal strokes of 90%, 96%,neurand 8% for SE stents at 3 years, and Chakhtoura et al,34 8%.
reas t
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compete with restenosis after endarterectomy, ranging from
4% to 22% for hemodynamic restenosis.35-38 Only one re-
Fig 3. Life-table analysis of all ipsilateral neurologic co
years from new ipsilateral neurologic events is 92%, whe
Fig 4. Left, Fresh and (right) repaired sample of the
(arrows). The patient, who was symptomatic, was operate
no in-stent restenosis, contrary to what was expected.port28 related a higher restenosis rate in patients treated byCAS, with a freedom from restenosis50% at 3 years of only
44%. This result relied only on 13 patients, however.
In our series, the ISR rate for lesions narrowing the
ations after carotid artery stenting. The freedom at 10
he ipsilateral stroke freedom is 98%.
ation (arrowhead) that developed just below the stent
and the carotid body was excised. The stent appears withmpliculcer
d onarterial lumen50% was low (6.8%). Some factors predict-
roup,
se in p
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tomatic lesions were found at higher risk of ISR. Further-
more we found that BE stents may lead to a higher IRS rate.
These results must be interpreted carefully, however, be-
cause the Fisher test does not have a high significance (P 
.055). Wholey and colleagues39 reported a vessel patency
(ISR50%) at 3 years of 96.3% for BE stents and 83.7% for
SE stents. Our results may be due to the longer follow-up
period we have on BE stents than with SE stents. The
influence of the type of stent will be investigated in future
works. More often, CS appears to heal the atheromatous
plaque with a thin endothelial layer. Other studies are
reporting that postendarterectomy stenosis is a predictive
factor of ISR.40
Should all carotid ISR be re-operated on? Most are
asymptomatic, and therefore, indications for redo therapy
Table III. Results of the Fisher test for lesion features and
Type of
predictive factors Factors
In-s
Total
No. (1)
N
f
Lesion factor Asymptomatic lesions 15
Technical factor Balloon expandable stent 13
*Table shows the number of cases, the global number of patients in each g
Table IV. Results of the Fisher test for lesion features and
Type of
predictive factors Factors
% with
among
Lesion factor Asymptomatic lesions 86
Technical factor Balloon expandable stent 84
ISR, in-stent restenosis.
*Table shows the percentage of factors in each group of patients, the increa
with no complications, and the P value.
Fig 5. Left, dilation of a compressed balloon-expandab
localization and morphology of the stent is achieved
tomography scan.must be modeled on that for recurrent stenosis after end-arterectomy. Symptoms should be the first consideration,41
and the degree of stenosis the second one. According to
O’Donnel et al,42 it is recommended that asymptomatic
recurrent stenosis75% be treated because of its long-term
evolution towards occlusion in 25% and recurrent stroke in
12.5%. The same could be applied for ISR 75% to be
redilated. In our experience, only one stroke (0.5%) oc-
curred after a severe ISR. We advise the use of protective
devices also in this case. We currently consider ISR as an
issue still to be possibly resolved in the future by coated
stents or drug therapy.
Stent deformity of balloon-expandable stents with a
rate 3% is not currently an issue, but therefore justifies
that their use should be limited to specific lesions that are
short and resistant to dilatation because of fibrosis, calcifi-
cation, or both, such as encountered in postsurgical or
nical factors on in-stent restenosis after carotid stenting*
estenosis Free from in-stent restenosis
P
h risk
(2) % (2/1)
Total
No.(3)
No. with risk
factor (4) % (4/3)
86.67 217 126 58.06 .039
84.62 201 120 59.70 .055
and the P value as a result of the Fisher test.
nical factors on in-stent restenosis after carotid stenting*
r % with factor amongst
free from ISR
Increase in
ISR risk P
58.06 1.49 .039
59.70 1.42 .055
ercentage between the group with complications compared with the group
nt under intravascular ultrasound guidance. Right, the
ugh three-dimensional reconstruction of a computedtech
tent r
o. wit
actor
13
11tech
facto
st ISR
.67
.62le ste
thropostradiotherapy restenosis.
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Late outcome of carotid artery stenting appears com-
petitive with surgery. Protection from late stroke appears
efficient and in-stent restenosis seems acceptable and
asymptomatic. In our experience, predictors for good early
and long-term results were female sex, age70 years, good
renal function, a symptomatic lesion located outside the
carotid bifurcation, and the use of antegrade cervical access.
Randomized trials with long-term follow-up are necessary
to evaluate this technique compared with surgery.
We thank Prof. Michel Roux and Mr. Jacques Bras,
Department of Medical Statistics, University Hospital of
Marseille, for their full involvement in this work and the
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This is one of the largest single-center series documenting
early and long-term outcomes after carotid angioplasty (CAS) in a
selected group of patients deemed “high-risk” for carotid endar-
terectomy (CEA). In particular, it is one of few published series
with 10-year follow-up data. Although it is inevitable that surgeons
will disagree with some of the criteria deemed to render patients at
higher risk for procedural stroke (asymptomatic atherosclerotic
stenosis, asymptomatic post-CEA restenosis, and asymptomatic
postradiation stenosis), the title of this paper (conveniently) shifts
debate away from patient selection to focus attention on lateskepticism of many surgeons regarding claims that the late results
of CAS are at least equivalent to CEA.
In this respect, the data from this paper clearly suggest that the
risk of long-term stroke after CAS is remarkably low (10-year
freedom from any stroke and ipsilateral stroke was 96% and 98%).
These results are much better than most contemporary surgical
series and represent an improvement on parallel data from the
European Carotid Surgery Trial (ECST), the North American
Symptomatic Carotid Endarterectomy Trial (NASCET), the
Asymptomatic Carotid Atherosclerosis Study (ACAS) and the
Asymptomatic Carotid Surgery Trial (ACST). None of the ran-
